About Oncimmune (LON:ONC)
Oncimmune Holdings Plc, an early cancer detection company, develops and commercializes products to diagnose cancer in the United Kingdom and North America. The company engages in the development of autoantibody assay technologies to allow cancer detection to a range of solid cancer tumor types. It offers EarlyCDT-Lung, a blood test, which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. The company also develops EarlyCDT tests for liver and ovarian cancer. Oncimmune Holdings Plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.
Industry, Sector and Symbol
Industry Diagnostics & Research
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity-95.26%
Return on Assets-81.13%
Oncimmune (LON:ONC) Frequently Asked Questions
What is Oncimmune's stock symbol?
Oncimmune trades on the London Stock Exchange (LON) under the ticker symbol "ONC."
How were Oncimmune's earnings last quarter?
Oncimmune Holdings PLC (LON:ONC) released its quarterly earnings data on Tuesday, February, 13th. The company reported ($5.70) EPS for the quarter. The firm earned $0.08 million during the quarter. Oncimmune had a negative return on equity of 95.26% and a negative net margin of 3,668.83%. View Oncimmune's Earnings History.
What price target have analysts set for ONC?
2 equities research analysts have issued 12-month target prices for Oncimmune's stock. Their predictions range from GBX 168 to GBX 169. On average, they expect Oncimmune's stock price to reach GBX 168.50 in the next twelve months. View Analyst Ratings for Oncimmune.
Who are some of Oncimmune's key competitors?
Some companies that are related to Oncimmune include MaxCyte (MXCT), Palatin Technologies (PTN), EPIGENOMICS AG/S (EPGNY), Profound Medical (PRN), Lexagene (LXG), Sernova (SVA), Co-Diagnostics (CODX), SQI Diagnostics (SQD), Parallax Health Sciences (PRLX), Cambridge Cognition (COG), LED Medical Diagnostics (LMD), 3D Signatures (DXD), GeneNews (GEN), Oxford Advanced Surfaces Gro (CRON) and Epistem (GDR).
Who are Oncimmune's key executives?
Oncimmune's management team includes the folowing people:
- Mr. Geoffrey Hamilton-Fairley, CEO & Director
- Mr. Andrew Millet BA, MBA, FCA, CFO, Company Sec. & Exec. Director (Age 50)
- Dr. Laura J. Peek, Principal Scientist and Assistant Lab Director
- Dr. Andrea Murray, Chief Operational Scientist
- Dr. James Jett, Chief Medical Officer
Has Oncimmune been receiving favorable news coverage?
News articles about ONC stock have trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Oncimmune earned a daily sentiment score of 0.05 on Accern's scale. They also assigned news headlines about the company an impact score of 45.36 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Oncimmune?
Shares of ONC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Oncimmune's stock price today?
One share of ONC stock can currently be purchased for approximately GBX 127.50.
How big of a company is Oncimmune?
Oncimmune has a market capitalization of £85.08 million.
How can I contact Oncimmune?
Oncimmune's mailing address is Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom. The company can be reached via phone at +44-115-8231869.
MarketBeat Community Rating for Oncimmune (ONC)MarketBeat's community ratings are surveys of what our community members think about Oncimmune and other stocks. Vote "Outperform" if you believe ONC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONC will underperform the S&P 500 over the long term. You may vote once every thirty days.